New antiarrhythmic drugs in treatment of atrial fibrillation
Authors:
M. Táborský; P. Neužil
Authors place of work:
kardiologické oddělení, Nemocnice Na Homolce, Praha
Published in the journal:
Kardiol Rev Int Med 2006, 8(4): 193-197
Category:
Editorial
Summary
Atrial fibrillation (AF) is associated with increased mortality and morbidity. AF causes a significant economical burden which has grown in the past decades and is expected to grow even further in the upcoming period with the increasing trend in AF prevalence and hospitalizations. Despite of success of advanced catheter ablation and surgical treatment of AF, pharmacological therapy stil remains the first-line approach in the treatment of AF. Nevertheless currently available antiarrhythmic drugs (AAD) are associated with a significant side effects including ventricular proarrhythmia. The goal is to develop more effective and safer AADs specifically targeting atrial tissue, especially for patiens with structural heart disease. This review is including selective multi-ion channel blockers and agents targeting the underlying pathophysiology, substrate alterations and inflammation. Additional new and safer pharmacological targets are likely to be identified as a part of complex treatment approach of this arrhythmia.
Keywords:
atrial fibrillation, antiarrhythmic drugs, pathophysiological mechanisms
Zdroje
1. Wellens HJ. Atrial fibrillation – the last big hurdle in treating supraventricular tachycardia. N Engl J Med 1994; 331: 944-945.
2. Ezekowitz MD. The epidemic of the new millennium. Ann Intern Med 1999; 131: 537-538.
3. Dell´Orfano JT, Patel H, Wolbrete DL et al. Acute treatment of atriall Fibrillation: spontaneous conversion rates and cost of care. Am J Cardiol 1999; 83: 788-790.
4. Podrid PJ. Amiodarone: Reevaluation of an old drug. Ann Intern Med 1995; 122: 689-700.
5. Fuster V, Ryden LE, Cannon DS et al. ACC/AHA/ESC 2006 guidelines for the Management of patients with atrial fibrillation – executive summary. Eur Heart J 2006; 27: 1979-2030.
6. Čihák R, Heinc P. Fibrilace síní: současné možnosti léčby aneb (stará) nová guidelines. Cor Vasa 2002; 44: 38-42.
7. Digitalis in Acute Atrial Fibrillation [DAAF] trial Group Investigators: Intravenous digoxin in acute atrial fibrillation: results of a randomized, placebo-controlled multicenter trial in 239 patients. Eur Heart J 1997; 18: 649-654.
8. Hohnloser SK, Kuck KH, Lilienthal J et al. Rhythm or rate control in atrial fibrillation [PIAF]: a randomised trial. Lancet 2000; 356: 1789-1794.
9. AFFIRM Investigators: A comparison of rate control and rhythm control in patients with atriall fibrillation. The Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] Investigators. N Engl J Med 2002; 347: 1825-1833.
10. VanGelder IC, Hagens VE, Bosker HA et al. A comparison of rate control and rhythm control in patients with reccurent persistent atrial fibrillation. N Eng J Med 2002; 347: 1834 -1840.
11. Wijffels MC, Kirchhof CJ, Dorland R et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968.
12. Nattel S. Atrial electrophysiological remodeling caused by rapid atrial activation: Underlying mechanisms and clinical relevance to atrial fibrillation. Cardiovasc Res 1999; 42: 298-308.
13. Mandapati R, Skanes A, Chen J et al. Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. Circulation 2000; 101: 194-199.
14. Jais P, Hocini M, Macie L et al. Distinctive electrophysiological properties of pulmonary veins in patients with atrial fibrillation. Circulation 2002; 106: 2479-2485.
15. Haissaguerre M, Jais P, Shah DC et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659-666.
16. Matsuo KTY, Uno K, Khrestian CM et al. A new mechanism of sustained atrial fibrillation: Studies in the canine sterile pericarditis model. Circulation 1998; 98(suppl): 209.
17. Fenelon G, Shepard RK, Stambler BS. Focal origin of atrial tachycardia in dogs with rapid ventricular pacing-induced heart failure. J Cardiovasc Electrophysiol 2003; 14: 1093-1102.
18. Nieuwlaat R, Capucci R, Camm JA et al. Atriall fibrillation management: a prospective survey in ESC member Countries. Eur Heart J 2005; 26: 2422-2434.
19. Wilson JS, Podrid PJ. Side effects from amiodarone. Am Heart J 1991; 21: 158-171.
20. Varro A, Takacs J, Nemeth M et al. Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: Comparison with amio-darone. Br J Pharmacol 2001; 133: 625-634.
21. Touboul P, Brugada J, Capucci A et al. Dronedarone for prevention of atrial fibrillation: A dose-ranging study. Eur Heart J 2003; 24: 1481-1487.
22. Singh BN, Connolly SJ, Roy D et al. The EURIDIS and ADONIS trials: Dronedarone for maintaining sinus rhythm in patients with atrial fibrillation/flutter. Circulation 2004; 110: (Abstract 3429).
23. Page RL, Conolly SJ, Wilkinson WE et al. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: Efficacy and dose-response. Am Heart J 2002; 143: 643-649.
24. Connolly SJ, Schnell DJ, Page RL et al. Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am J Cardiol 2001; 88: 974-979.
25. Pratt CM, Singh SN, Al-Khalidi HR et al. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: Results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol 2003; 108 (suppl 4): 507.
26. Dukes ID, Morad M. Tedisamil inactivates transient outward K+ current in rat ventri-cular myocytes. Am J Physiol 1989; 257: H1746-H1749.
27. Li D, Benardeau A, Nattel S. Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. Circulation 2000; 102: 104-112.
28. Blaauw Y, Gogelein H, Tieleman RG et al. „Early“ class III drugs for the treatment of atrial fibrillation: Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004; 110: 1717-1724.
29. Goldstein RN, Khrestian C, Carlsson L et al. AZD7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 2004; 15: 1444-1450.
30. Hollander W, Michelson AL, Wilkins RW. Serotonin and antiserotonins I. Their circulatory, respiratory and renal effects in man. Circulation 1957; 16: 246-255.
31. Rahme MM, Cotter B, Leistad E et al. Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT(4) receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. Circulation 1999; 100: 2010-2017.
32. Goette A, Arndt M, Rocken C et al. Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 2000; 101: 2678-2681.
33. Pedersen OD, Bagger H, Kober L et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-380.
34. Ueng KC, Tsai TP, Yu WC et al. Use of enalapril to facilitate sinus rhythm mainte-nance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090-2098.
35. Maggioni AP, Latini R, Carson PE et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Trial (Val-HeFT). Am Heart J 2005; 149: 548-557.
36. Zannad F, Alla F, Dousset B et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients withcongestive heart failure: Insights from the randomized aldactone evaluation study (RALES). Rales investigators. Circulation 2000; 102: 2700-2706.
37. Chung MK, Martin DO, Sprecher D et al. C-reactive protein elevation in patientswith atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
38. Goldstein RNKC, Kyungmoo R, Van Wagoner DR et al. Prevention of post-operative atrial fibrillation and flutter using steroids (abstract). PACE 2003; 26: 1058.
39. Shiroshita-Takeshita A, Schram G, Lavole J et al. Effect of simvastatin and anti-oxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 2004; 110: 2313-2319.
40. Wyse DG, Waldo AL, Di Marco JP et al. A comparison of rate control and rhythmcontrol in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
41. Prystowsky EN, Niazi I, Curtis AB et al. Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510), a novel A1-adenosine receptor agonist. J Am Coll Cardiol 2003; 42: 1098-1102.
Štítky
Paediatric cardiology Internal medicine Cardiac surgery CardiologyČlánok vyšiel v časopise
Cardiology Review
2006 Číslo 4
Najčítanejšie v tomto čísle
- Pacemaker automatic functions
- Measurement of heart stability
- Treatment of hypertension in chronic renal insufficiency
- New antiarrhythmic drugs in treatment of atrial fibrillation